サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427827

オンコロジー向けジェネリック医薬品の世界市場レポート 2024

Generic Oncology Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
オンコロジー向けジェネリック医薬品の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

オンコロジー向けジェネリック医薬品の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.6%の年間複合成長率（CAGR）で355億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、バイオシミラーの承認、競合の激化、遠隔医療と遠隔医療の統合、個別化された治療パラダイム、価格圧力などの要因に関連している可能性があります。予測期間中に予想される注目すべき動向には、医薬品安全性監視への重点の強化、規制プロセスの合理化、併用療法の重視、高精度のジェネリック腫瘍治療薬の開発、およびより広範な市場アクセスが含まれます。

オンコロジー向けジェネリック医薬品市場の予想される成長は、がん患者の大幅な増加によって促進されると予想されます。さまざまな臓器に影響を与える制御されていない細胞増殖を特徴とするがんは、重大な罹患率と死亡率を伴い、世界の健康上の重大な課題を引き起こしています。費用対効果の高いオンコロジー向けジェネリック医薬品を利用できることは、がん治療、必須治療へのアクセスの強化、市場競争の促進、ヘルスケア費の削減にとって非常に重要です。 2022年 1月の国立がん研究所（NCI）によると、米国人口の約5.4%（1,810万人に相当）ががん生存者でした。さらに、623,405人が転移性がんを抱えており、2025年までに693,452人に増加すると予測されており、がんの影響が増大していることが強調されています。したがって、がん患者の大幅な増加がオンコロジー向けジェネリック医薬品市場の成長の原動力となっています。

個別化医療に対する需要の高まりも、オンコロジー向けジェネリック医薬品市場の成長を促進する態勢が整っています。進化する医療アプローチである個別化医療は、患者固有の遺伝的要因、環境要因、ライフスタイル要因に基づいて個々の患者に合わせた治療を行います。 オンコロジー向けジェネリック医薬品は個別化医療において重要な役割を果たし、個々の患者のニーズに応える費用対効果の高い代替手段を提供し、標的を絞った特殊ながん治療への広範なアクセスに貢献します。たとえば、2021年9月、スウェーデン政府はゲノム医療スウェーデン（GMS）の国家インフラを強化するために2億2,000万スウェーデンクローナ（187万米ドル）を割り当てました。この投資は、精密医療をスウェーデンのヘルスケアシステムにシームレスに統合し、個別化医療の需要の高まりに合わせて、正確な検査と個別化されたケアへの広範なアクセスを確保することを目的としています。したがって、個別化医療に対する需要の高まりが、オンコロジー向けジェネリック医薬品市場の成長の主な原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のオンコロジー向けジェネリック医薬品市場、分子タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 高分子
  • 低分子
  • 世界のオンコロジー向けジェネリック医薬品市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 世界のオンコロジー向けジェネリック医薬品市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 管理医療機関

第7章 地域および国の分析

  • 世界のオンコロジー向けジェネリック医薬品市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のオンコロジー向けジェネリック医薬品市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • オンコロジー向けジェネリック医薬品市場の競合情勢
  • オンコロジー向けジェネリック医薬品市場の企業プロファイル
    • Pfizer Inc.
    • AbbVie
    • Novartis AG
    • Bristol-Myers Squibb Company
    • AstraZeneca Plc

第31章 その他の大手および革新的な企業

  • Abbott Laboratories
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Eli Lilly and Company
  • Merck &Co. Inc.
  • Becton Dickinson and Company
  • Baxter International Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Aurobindo Pharma Limited
  • Cipla Inc.
  • Hikma Pharmaceuticals
  • Endo Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13671

Generic oncology drugs are medications designed for cancer treatment, produced by different pharmaceutical companies after the expiration of patent protection for the original brand-name drug. These generic drugs contain identical active ingredients and share the same dosage forms, strength, route of administration, and intended use as the original brand-name drug.

Generic oncology drugs encompass two main types of molecules large molecules and small molecules. Large molecules, also known as biologics, are intricate molecules derived from living organisms, such as proteins, antibodies, or nucleic acids. Trastuzumab (Herceptin), an example of a large molecule-based generic oncology drug, is utilized in cancer treatment by targeting specific proteins or receptors on cancer cells. These drugs can be administered through oral and parenteral routes and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and managed care institutions.

The generic oncology drugs research report is one of a series of new reports from The Business Research Company that provides generic oncology drugs market statistics, including the generic oncology drugs industry's global market size, regional shares, competitors with a generic oncology drugs market share, detailed generic oncology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the generic oncology drugs industry. This generic oncology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The generic oncology drugs market size has grown strongly in recent years. It will grow from $25.64 billion in 2023 to $27.56 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period can be ascribed to factors such as patent expirations, initiatives for healthcare cost containment, rising cancer prevalence, expanded health insurance coverage, and the prescribing practices of physicians

The generic oncology drugs market size is expected to see strong growth in the next few years. It will grow to $35.54 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be associated with factors such as biosimilar approvals, heightened competition, the integration of telemedicine and remote care, a personalized treatment paradigm, and pricing pressures. Notable trends expected in the forecast period encompass heightened focus on pharmacovigilance, streamlined regulatory processes, an emphasis on combination therapies, the development of precision generic oncology medications, and broader market access.

The anticipated growth in the generic oncology drugs market is expected to be propelled by a significant increase in cancer patients. Cancer, characterized by uncontrolled cell growth impacting various organs, poses a considerable global health challenge with significant morbidity and mortality. The availability of cost-effective generic oncology drugs is crucial for cancer treatment, enhancing access to essential therapies, fostering market competition, and reducing healthcare costs. According to the National Cancer Institute (NCI) in January 2022, approximately 5.4% of the US population, equivalent to 18.1 million individuals, were cancer survivors. Moreover, 623,405 people were living with metastatic cancer types, projected to increase to 693,452 by 2025, emphasizing the growing impact of cancer. Consequently, the significant rise in cancer patients is a driving force behind the growth of the generic oncology drugs market.

The increasing demand for personalized medicine is also poised to drive the growth of the generic oncology drugs market. Personalized medicine, an evolving medical approach, tailors treatments to individual patients based on their unique genetic, environmental, and lifestyle factors. Generic oncology drugs play a vital role in personalized medicine, offering cost-effective alternatives that cater to individual patient needs and contribute to broader accessibility to targeted and specialized cancer treatments. For example, in September 2021, the Swedish Government allocated SEK 220 million ($1.87 million) to enhance the national infrastructure of Genomic Medicine Sweden (GMS). This investment aims to seamlessly integrate precision medicine into the Swedish healthcare system, ensuring widespread access to precise tests and individualized care, aligning with the increasing demand for personalized medicines. Hence, the rising demand for personalized medicine is a key driver of the generic oncology drugs market's growth.

A notable trend is the emergence of novel formulations, which major companies are actively pursuing in the generic oncology drugs market. These companies are concentrating on the development of innovative drug delivery systems, modified-release formulations, and alternative dosage forms to enhance patient compliance and maintain their market standing. For example, in January 2023, MSN Laboratories Private Limited, an India-based pharmaceutical company specializing in generic drugs, introduced Palborest, the world's first generic Palbociclib tablets for advanced breast cancer treatment. This generic breast cancer drug provides a cost-effective alternative to the innovator tablet while ensuring bioequivalence. Its tablet form offers advantages over capsules, allowing administration with or without food and co-administration with proton pump inhibitors or antacids. Moreover, the tablet formulation is lactose- and gelatin-free, contributing to the drug's efficacy.

Major players in the generic oncology drugs market are intensifying efforts to introduce high-quality treatment options such as Bortezomib to enhance their competitive position. Bortezomib, a proteasome inhibitor used for multiple myelomas and certain lymphomas, inhibits cancer cell growth, thereby improving therapeutic outcomes. For instance, in May 2022, Gland Pharma, an India-based company, launched the generic cancer treatment drug Bortezomib in the US market. This drug, therapeutically equivalent to Takeda Pharmaceuticals' product, aims to offer an affordable and high-quality treatment alternative for US patients.

In March 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, completed the acquisition of Seagen Inc. for $43 billion. This strategic move aligns with Pfizer's goal to reinforce its market presence as a prominent player in the oncology sector. By incorporating Seagen's diverse range of medicines, Pfizer significantly strengthens and complements its existing oncology portfolio. Seagen Inc. is a US-based manufacturer of brentuximab vedotin (ADCETRIS), a cancer drug.

Major companies operating in the generic oncology drugs market report are Pfizer Inc., AbbVie, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Fresenius Kabi AG, GlaxoSmithKline PLC, Eli Lilly and Company, Merck & Co. Inc., Becton Dickinson and Company, Baxter International Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Hikma Pharmaceuticals, Endo Pharmaceuticals Inc., Aspen Pharmacare Holdings Limited, Lupin Limited, Towa Pharmaceutical Co Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Accord Healthcare

North America was the largest region in the generic oncology drugs market in 2023. The regions covered in the generic oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generic oncology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generic oncology drugs market consists of sales of paclitaxel, cyclophosphamide, gemcitabine, and fluorouracil. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generic Oncology Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generic oncology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generic oncology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generic oncology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Molecule Type: Large Molecule; Small Molecule
  • 2) By Route of Administration: Oral; Parenteral
  • 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Managed Care Institutions
  • Companies Mentioned: Pfizer Inc.; AbbVie; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca Plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Generic Oncology Drugs Market Characteristics

3. Generic Oncology Drugs Market Trends And Strategies

4. Generic Oncology Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Generic Oncology Drugs Market Size and Growth

  • 5.1. Global Generic Oncology Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Generic Oncology Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Generic Oncology Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Generic Oncology Drugs Market Segmentation

  • 6.1. Global Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Large Molecule
  • Small Molecule
  • 6.2. Global Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.3. Global Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Managed Care Institutions

7. Generic Oncology Drugs Market Regional And Country Analysis

  • 7.1. Global Generic Oncology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Generic Oncology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Generic Oncology Drugs Market

  • 8.1. Asia-Pacific Generic Oncology Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Generic Oncology Drugs Market

  • 9.1. China Generic Oncology Drugs Market Overview
  • 9.2. China Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Generic Oncology Drugs Market

  • 10.1. India Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Generic Oncology Drugs Market

  • 11.1. Japan Generic Oncology Drugs Market Overview
  • 11.2. Japan Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Generic Oncology Drugs Market

  • 12.1. Australia Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Generic Oncology Drugs Market

  • 13.1. Indonesia Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Generic Oncology Drugs Market

  • 14.1. South Korea Generic Oncology Drugs Market Overview
  • 14.2. South Korea Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Generic Oncology Drugs Market

  • 15.1. Western Europe Generic Oncology Drugs Market Overview
  • 15.2. Western Europe Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Generic Oncology Drugs Market

  • 16.1. UK Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Generic Oncology Drugs Market

  • 17.1. Germany Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Generic Oncology Drugs Market

  • 18.1. France Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Generic Oncology Drugs Market

  • 19.1. Italy Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Generic Oncology Drugs Market

  • 20.1. Spain Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.15. Spain Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Generic Oncology Drugs Market

  • 21.1. Eastern Europe Generic Oncology Drugs Market Overview
  • 21.2. Eastern Europe Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Generic Oncology Drugs Market

  • 22.1. Russia Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Generic Oncology Drugs Market

  • 23.1. North America Generic Oncology Drugs Market Overview
  • 23.2. North America Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Generic Oncology Drugs Market

  • 24.1. USA Generic Oncology Drugs Market Overview
  • 24.2. USA Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Generic Oncology Drugs Market

  • 25.1. Canada Generic Oncology Drugs Market Overview
  • 25.2. Canada Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Generic Oncology Drugs Market

  • 26.1. South America Generic Oncology Drugs Market Overview
  • 26.2. South America Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Generic Oncology Drugs Market

  • 27.1. Brazil Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Generic Oncology Drugs Market

  • 28.1. Middle East Generic Oncology Drugs Market Overview
  • 28.2. Middle East Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Generic Oncology Drugs Market

  • 29.1. Africa Generic Oncology Drugs Market Overview
  • 29.2. Africa Generic Oncology Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Generic Oncology Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Generic Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Generic Oncology Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Generic Oncology Drugs Market Competitive Landscape
  • 30.2. Generic Oncology Drugs Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AbbVie
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol-Myers Squibb Company
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca Plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Generic Oncology Drugs Market Other Major And Innovative Companies

  • 31.1. Abbott Laboratories
  • 31.2. Fresenius Kabi AG
  • 31.3. GlaxoSmithKline PLC
  • 31.4. Eli Lilly and Company
  • 31.5. Merck & Co. Inc.
  • 31.6. Becton Dickinson and Company
  • 31.7. Baxter International Inc.
  • 31.8. Mylan N.V.
  • 31.9. Sun Pharmaceutical Industries Ltd.
  • 31.10. Teva Pharmaceutical Industries Ltd.
  • 31.11. Dr. Reddy's Laboratories Ltd.
  • 31.12. Aurobindo Pharma Limited
  • 31.13. Cipla Inc.
  • 31.14. Hikma Pharmaceuticals
  • 31.15. Endo Pharmaceuticals Inc.

32. Global Generic Oncology Drugs Market Competitive Benchmarking

33. Global Generic Oncology Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Generic Oncology Drugs Market

35. Generic Oncology Drugs Market Future Outlook and Potential Analysis

  • 35.1 Generic Oncology Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Generic Oncology Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Generic Oncology Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer